Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence and 10-year booster study of Nimenrix versus prior comparators
2013-001549-15Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease and meningococcal meningitis (3 cohorts), sponsored by Pfizer. Primary endpoints: rSBA-MenA titres, rSBA-MenC titres and 2 more. Started Aug 2013; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal diseasemeningococcal meningitis
Beyond the preview
Go deeper on 2013-001549-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001549-15.